Your browser doesn't support javascript.
loading
Rationale and design of Apo-I Event Reduction in Ischemic Syndromes I (AEGIS-I): A phase 2b, randomized, placebo-controlled, dose-ranging trial to investigate the safety and tolerability of CSL112, a reconstituted, infusible, human apoA-I, after acute myocardial infarction.
Gibson, C Michael; Korjian, Serge; Tricoci, Pierluigi; Daaboul, Yazan; Alexander, John H; Steg, Philippe G; Lincoff, A Michael; Kastelein, John J P; Mehran, Roxana; D'Andrea, Denise; Merkely, Bela; Zarebinski, Maciej; Ophius, Ton Oude; Harrington, Robert A.
Afiliação
  • Gibson CM; PERFUSE Study Group, Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical, Harvard Medical School, Boston, MA. Electronic address: mgibson@bidmc.harvard.edu.
  • Korjian S; PERFUSE Study Group, Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical, Harvard Medical School, Boston, MA.
  • Tricoci P; Duke Clinical Research Institute, Department of Medicine, Duke University, Durhman, NC.
  • Daaboul Y; PERFUSE Study Group, Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical, Harvard Medical School, Boston, MA.
  • Alexander JH; Duke Clinical Research Institute, Department of Medicine, Duke University, Durhman, NC.
  • Steg PG; INSERM-Unité 1148, France Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, France Université Paris-Diderot, Sorbonne-Paris Cité, France National Heart and Lung Institute, Imperial College London, UK Institute of Cardiovascular Medicine and Science, Royal Brompton Hospital, United Kingdom.
  • Lincoff AM; Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH.
  • Kastelein JJ; Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
  • Mehran R; Columbia University Medical Center and the Cardiovascular Research Foundation, New York, NY.
  • D'Andrea D; CSL Behring, LLC, King of Prussia, PA.
  • Merkely B; Heart and Vascular Center, Semmelweis University, Városmajor str. 68, Budapest, Hungary.
  • Zarebinski M; Department of Cardiology, Warsaw Medical University, Warsaw, Poland.
  • Ophius TO; Department of Cardiology, Canisius Wilhelmina Ziekenhuis, Nijmegen, The Netherlands.
  • Harrington RA; Department of Medicine, Stanford University, Stanford, CA.
Am Heart J ; 180: 22-8, 2016 Oct.
Article em En | MEDLINE | ID: mdl-27659879
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Lipoproteínas HDL / Infarto do Miocárdio Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Adult / Female / Humans / Male Idioma: En Revista: Am Heart J Ano de publicação: 2016 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Lipoproteínas HDL / Infarto do Miocárdio Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Adult / Female / Humans / Male Idioma: En Revista: Am Heart J Ano de publicação: 2016 Tipo de documento: Article